Skip to content

Study · Randomized controlled trial · n = 61 · 2020

6 results

A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.

Webb DR, Htike ZZ, Swarbrick DJ, Brady EM, Gray LJ, Biglands J, Gulsin GS, Henson J, Khunti K, McCann GP, Waller HL, Webb MA and 5 more

Show all authors

Sargeant JA, Sargeant JA, Yates T, Zaccardi F, Davies MJ

Diabetes, obesity & metabolism1 Apr 2020Cited by 18 (Europe PMC)

PMID32157772 (opens in a new tab)DOI10.1111/dom.14023 (opens in a new tab)PepBankPUB-32157772
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, liraglutide and sitagliptin did not differ significantly in change in circumferential peak early diastolic strain rate after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide and sitagliptin did not differ in a heart relaxation measure after 26 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeCircumferential PEDSR change
    Study

    n = 61

    Comparator
    Sitagliptin
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    PEDSR change difference
    −0.01 s-1
    liraglutide vs sitagliptin

    Source sentences

    Summary
    There were no statistically significant between-group differences (intention-to-treat; mean [95% confidence interval]) in PEDSR change (-0.01 [-0.07, +0.06] s-1 ), left ventricular ejection fraction (-1.98 [-4.90, +0.94]%), left ventricular mass (+1.14 [-5.23, +7.50] g) or aortic distensi…
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, left ventricular ejection fraction did not differ significantly between liraglutide and sitagliptin after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide and sitagliptin did not differ in heart pumping fraction after 26 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeLeft ventricular ejection fraction
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    LVEF difference
    −1.98%
    liraglutide vs sitagliptin

    Source sentences

    Summary
    There were no statistically significant between-group differences (intention-to-treat; mean [95% confidence interval]) in PEDSR change (-0.01 [-0.07, +0.06] s-1 ), left ventricular ejection fraction (-1.98 [-4.90, +0.94]%), left ventricular mass (+1.14 [-5.23, +7.50] g) or aortic distensi…
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, left ventricular mass did not differ significantly between liraglutide and sitagliptin after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide and sitagliptin did not differ in heart muscle mass after 26 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeLeft ventricular mass
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    LV mass difference
    1.14 g
    liraglutide vs sitagliptin

    Source sentences

    Summary
    There were no statistically significant between-group differences (intention-to-treat; mean [95% confidence interval]) in PEDSR change (-0.01 [-0.07, +0.06] s-1 ), left ventricular ejection fraction (-1.98 [-4.90, +0.94]%), left ventricular mass (+1.14 [-5.23, +7.50] g) or aortic distensi…
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, aortic distensibility did not differ significantly between liraglutide and sitagliptin after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide and sitagliptin did not differ in aortic stretchiness after 26 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeAortic distensibility
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Aortic distensibility difference
    −0.35 mmHg-1 x 10-3
    liraglutide vs sitagliptin

    Source sentences

    Summary
    There were no statistically significant between-group differences (intention-to-treat; mean [95% confidence interval]) in PEDSR change (-0.01 [-0.07, +0.06] s-1 ), left ventricular ejection fraction (-1.98 [-4.90, +0.94]%), left ventricular mass (+1.14 [-5.23, +7.50] g) or aortic distensi…
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, liraglutide reduced HbA1c more than sitagliptin after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide lowered HbA1c more than sitagliptin over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    HbA1c difference
    −4.57 mmol/mol
    liraglutide vs sitagliptin

    Source sentences

    Summary
    Reductions in HbA1c (-4.57 [-9.10, -0.37] mmol mol-1 ) and body weight (-3.88 [-5.74, -2.01] kg) were greater with liraglutide.
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In young adults with obesity and type 2 diabetes, liraglutide reduced body weight more than sitagliptin after 26 weeks.

    In plain wordsIn young adults with obesity and type 2 diabetes, liraglutide lowered body weight more than sitagliptin over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Body weight difference
    −3.88 kg
    liraglutide vs sitagliptin

    Source sentences

    Summary
    Reductions in HbA1c (-4.57 [-9.10, -0.37] mmol mol-1 ) and body weight (-3.88 [-5.74, -2.01] kg) were greater with liraglutide.
    1 context sentence
    Summary · context
    In a prospective, randomized, open-label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin treated young (aged 18-50 years) adults with obesity and type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.